CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.

Blood
Andreas DörrschuckW Herr

Abstract

Allogeneic hematopoietic stem cell transplantation can induce considerable tumor remissions in metastatic renal-cell carcinoma (RCC) patients. The precise effector mechanisms mediating these graft-versus-tumor reactions are unknown. We studied RCC-directed CD8(+) T-cell responses in blood lymphocytes of healthy individuals matched with established RCC cell lines for HLA-class I. In 21 of 22 allogeneic mixed lymphocyte/tumor-cell cultures (MLTCs), RCC-reactive cytotoxic T-lymphocytes (CTLs) were readily obtained. From MLTCs, 121 CD8(+) CTL clones with memory phenotype were isolated. Their anti-RCC reactivity was restricted by multiple classical HLA-Ia molecules, in particular by HLA-A2, -A3, -B7, -B44, -Cw7, and by a nonclassical HLA-Ib determinant. Extensive cross-reactivity analyses on a broad target panel identified CTLs that recognize antigens with expression restricted to renal tissue or to renal and colon tumors. Other CTLs were directed against antigens with broader tissue distribution being expressed in various epithelial and nonepithelial tumors or, additionally, in hematopoietic cells. With microcapillary liquid chromatography and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF)/TOF mass spectrome...Continue Reading

References

Dec 27, 1990·The New England Journal of Medicine·K FleischhauerS Y Yang
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P D EnnisP Parham
Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A J McMichaelJ L Strominger
Jan 1, 1987·Molecular and Cellular Biology·R B DuBridgeM P Calos
Jan 1, 1982·Hybridoma·A E BergerP Cresswell
Aug 1, 1981·Human Immunology·J M PesandoS F Schlossman
Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
Oct 1, 1994·Tissue Antigens·A Steinle, D J Schendel
Dec 1, 1994·Clinical Immunology and Immunopathology·K D Moudgil, E E Sercarz
Dec 15, 1994·International Journal of Cancer. Journal International Du Cancer·H BernhardK H Meyer zum Büschenfelde
Jan 1, 1993·Annual Review of Immunology·L A Sherman, S Chattopadhyay
May 16, 1996·International Journal of Cancer. Journal International Du Cancer·A CaignardP Y Dietrich
Jun 1, 1997·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·D J SchendelE Nössner
Mar 12, 1998·International Journal of Cancer. Journal International Du Cancer·I SaeterdalG Gaudernack
Feb 27, 1999·Current Opinion in Immunology·V M BraudA J McMichael
Aug 4, 1999·Cancer Immunology, Immunotherapy : CII·U Elsässer-BeileJ Schulte Mönting
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·W HerrW J Storkus
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Jun 14, 2000·Immunologic Research·L A ShermanJ Biggs
Mar 26, 2002·FEBS Letters·Stefano Confalonieri, Pier Paolo Di Fiore
Apr 12, 2002·International Journal of Cancer. Journal International Du Cancer·Constantin N BaxevanisMichael Papamichail

❮ Previous
Next ❯

Citations

Mar 10, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Christiane GeigerDolores J Schendel
Dec 30, 2006·Cancer Immunology, Immunotherapy : CII·Ilaria LionelloCatia Traversari
Mar 27, 2010·Journal of Biomedicine & Biotechnology·Elisabetta CavalcantiElena Ranieri
Dec 13, 2005·Expert Review of Anticancer Therapy·Robert O Dillman
Jun 29, 2011·Expert Review of Anticancer Therapy·Marco BregniUNKNOWN Solid Tumor Working Party of EBMT
Mar 23, 2011·Expert Opinion on Biological Therapy·Scott S TykodiJohn A Thompson
Jul 28, 2007·Seminars in Cancer Biology·Bernhard FrankenbergerDolores J Schendel
Mar 21, 2008·International Journal of Cancer. Journal International Du Cancer·Matteo LandriscinaElena Ranieri
Jul 17, 2015·PLoS Pathogens·Simone ThomasNiels A W Lemmermann
Apr 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthias LeisegangElfriede Noessner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved